Prostate cancer cell proliferation is influenced by leptin

Journal of Surgical Research

Volumn 118, Issue 1, 2004, Pages 71-82

  Somasundar, Ponnandai ^a,b   Frankenberry, Krista A ^b   Skinner, Heath ^c   Vedula, Giridhar ^d   McFadden, David W ^b   Riggs, Dale ^b   Jackson, Barbara ^b   Vangilder, Reyna ^b   Hileman, Stanley M ^b   Vona Davis, Linda C ^b  

^a Clarksburg Louis A Johnson VA Medical Center   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell proliferation; Extracellular signal regulated kinase (ERK); Leptin receptors; Phosphatidylinositol 3 kinase (PI3K); Prostate cancer; Suppressor of cytokine signaling (SOCS 3)

Indexed keywords

LEPTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUPPRESSOR OF CYTOKINE SIGNALING;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; HUMAN; HUMAN CELL; MALE; NUCLEOSOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME ACTIVATION; HUMANS; LEPTIN; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, CELL SURFACE; REPRESSOR PROTEINS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS;

EID: 11144356894     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.01.017     Document Type: Article

References (53)

1. Vona-Davis L., Vedula G., McFadden D.W., VanGilder R., Hileman S.M. Identification of Leptin Receptor Isoforms in Human Prostate. 2003;. 37th Annual Meeting of the Association for Academic Surgery, Sacramento, CA, Program Abstract P.
2. Carroll K.K. Obesity as a risk factor for certain types of cancer. Lipids. 33:1998;1055.
3. Vona-Davis L., Skinner H., Jackson B., Riggs D., Somasundar P., McFadden D.W. Leptin activates MAPK signaling in human breast and prostate cancer. J. Surg. Res. 114:2003;300.
4. Klein S., Wadden T., Sugerman H.J. AGA technical review on obesity. Gastroenterology. 123:2002;882.
5. Mantzoros C.S., Flier J.S. Editorial leptin as a therapeutic agent - trials and tribulations. J. Clin. Endocrinol. Metab. 85:2000;4000.
6. Gao N., Zhang Z., Jiang B.H., Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310:2003;1124.
7. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348:2003;1625.
8. Vona-Davis L., Vedula G., McFadden D.W., VanGilder R., Somasundar P., Hileman S.M. Identification of leptin receptor isoforms in human prostate cancer cells. J. Surg. Res. 114:2003;302.
9. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 94:2002;1704.
10. Romero Y., Cameron A.J., Locke G.R. III, Schaid D.J., Slezak J.M., Branch C.D., Melton L.J. III. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 113:1997;1449.
11. Rose D.P., Gilhooly E.M., Nixon D.W. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. [Review] Int. J. Oncol. 21:2002;1285.
12. Schapira D.V., Kumar N.B., Lyman G.H., Cox C.E. Obesity and body fat distribution and breast cancer prognosis. Cancer. 67:1991;523.
13. van den Brandt P.A., Spiegelman D., Yaun S.S., Adami H.O., Beeson L., Folsom A.R., Fraser G., Goldbohm R.A., Graham S., Kushi L., Marshall J.R., Miller A.B., Rohan T., Smith-Warner S.A., Speizer F.E., Willett W.C., Wolk A., Hunter D.J. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am. J. Epidemiol. 152:2000;514.
14. Wolf G., Chen S., Han D.C., Ziyadeh F.N. Leptin and renal disease. Am. J. Kidney Dis. 39:2002;1.
15. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:1995;543.
16. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425.
17. Mantzoros C.S. The role of leptin in human obesity and disease a review of current evidence. Ann. Intern. Med. 130:1999;671.
18. Ahima R.S., Flier J.S. Leptin. Annu. Rev. Physiol. 62:2000;413.
19. Friedman J.M. Leptin, leptin receptors, and the control of body weight. Nutr. Rev. 56:1998;s38.
20. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature. 395:1998;763.
21. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334:1996;292.
22. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects correlations with insulin resistance. Eur. J. Endocrinol. 149:2003;331.
23. Fei H., Okano H.J., Li C., Lee G.H., Zhao C., Darnell R., Friedman J.M. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc. Natl. Acad. Sci. USA. 94:1997;7001.
24. Bjorbaek C., Uotani S., da Silva B., Flier J.S. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J. Biol. Chem. 272:1997;32686.
25. Murakami T., Yamashita T., Iida M., Kuwajima M., Shima K. A short form of leptin receptor performs signal transduction. Biochem. Biophys. Res. Commun. 231:1997;26.
26. Yamashita T., Murakami T., Otani S., Kuwajima M., Shima K. Leptin receptor signal transduction OBRa and OBRb of fa type. Biochem. Biophys. Res. Commun. 246:1998;752.
27. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Jr. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275:2000;14563.
28. Bjorbak C., Lavery H.J., Bates S.H., Olson R.K., Davis S.M., Flier J.S., Myers M.G. Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275:2000;40649.
29. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell. 1:1998;619.
30. Bjorbaek C., El Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 274:1999;30059.
31. Emilsson V., Arch J.R., de Groot R.P., Lister C.A., Cawthorne M.A. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 455:1999;170.
32. Ziotopoulou M., Erani D.M., Hileman S.M., Bjorbaek C., Mantzoros C.S. Unlike leptin, ciliary neurotrophic factor does not reverse the starvation-induced changes of serum corticosterone and hypothalamic neuropeptide levels but induces expression of hypothalamic inhibitors of leptin signaling. Diabetes. 49:2000;1890.
33. Tsumanuma I., Jin L., Zhang S., Bayliss J.M., Scheithauer B.W., Lloyd R.V. Leptin signal transduction in the HP75 human pituitary cell line. Pituitary. 3:2000;211.
34. Chang S., Hursting S.D., Contois J.H., Strom S.S., Yamamura Y., Babaian R.J., Troncoso P., Scardino P.S., Wheeler T.M., Amos C.I., Spitz M.R. Leptin and prostate cancer. Prostate. 46:2001;62.
35. Saglam K., Aydur E., Yilmaz M., Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J. Urol. 169:2003;1308.
36. Stattin P., Soderberg S., Hallmans G., Bylund A., Kaaks R., Stenman U.H., Bergh A., Olsson T. Leptin is associated with increased prostate cancer risk a nested case-referent study. J. Clin. Endocrinol. Metab. 86:2001;1341.
37. Dahle S.E., Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., Hsing A.W. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 168:2002;599.
38. Hsing A.W., Chua S. Jr, Gao Y.T., Gentzschein E., Chang L., Deng J., Stanczyk F.Z. Prostate cancer risk and serum levels of insulin and leptin a population-based study. J. Natl. Cancer Inst. 93:2001;783.
39. Lagiou P., Signorello L.B., Trichopoulos D., Tzonou A., Trichopoulou A., Mantzoros C.S. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int. J. Cancer. 76:1998;25.
40. Stattin P., Kaaks R., Johansson R., Gislefoss R., Soderberg S., Alfthan H., Stenman U.H., Jellum E., Olsson T. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 12:2003;474.
41. Somasundar P., Yu A., Vona-Davis L., McFadden D.W. Differential responses of leptin on cancer in vitro. J. Surg. Res. 113:2002;50.
42. Dieudonne M.N., Machinal-Quelin F., Serazin-Leroy V., Leneveu M.C., Pecquery R., Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 293:2002;622.
43. Hardwick J.C., Van Den Brink G.R., Offerhaus G.J., Van Deventer S.J., Peppelenbosch M.P. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 121:2001;79.
44. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 94:2002;1704.
45. Laud K., Gourdou I., Pessemesse L., Peyrat J.P., Djiane J. Identification of leptin receptors in human breast cancer functional activity in the T47-D breast cancer cell line. Mol. Cell. Endocrinol. 188:2002;219.
46. Onuma M., Bub J.D., Rummel T.L., Iwamoto Y. Prostate cancer cell-adipocyte interaction leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 278:2003;42660.
47. Park H.Y., Kwon H.M., Lim H.J., Hong B.K., Lee J.Y., Park B.E., Jang Y., Cho S.Y., Kim H.S. Potential role of leptin in angiogenesis leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp. Mol. Med. 33:2001;95.
48. Somasundar P., McFadden D.W., Hileman S.M., Vona-Davis L.C. Leptin is a growth factor in cancer. J. Surg. Res. 116:2004;337.
49. Onuma M., Bub J.D., Rummel T.L., Iwamoto Y. Prostate cancer cell-adipocyte interaction leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 278:2003;42660.
50. Sanchez-Margalet V., Martin-Romero C., Santos-Alvarez J., Goberna R., Najib S., Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells mechanisms of action. Clin. Exp. Immunol. 133:2003;11.
51. Vona-Davis L., Riggs D., Jackson B., Somasundar P., McFadden D.W. Leptin Suppresses Apoptosis in Prostate Cancer In Vitro. 2003;. [Abstract]. American Association for Cancer Research 2003 Annual Meeting, Washington, DC
52. Blumenstein M., Bowen-Shauver J.M., Keelan J.A., Mitchell M.D. Identification of suppressors of cytokine signaling (SOCS) proteins in human gestational tissues differential regulation is associated with the onset of labor. J. Clin. Endocrinol. Metab. 87:2002;1094.
53. Wu J., Haugk K., Plymate S.R. Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. Horm. Metab. Res. 35:2003;751.